openPR Logo
Press release

Hodgkin's Lymphoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals and Many Others

02-21-2023 08:31 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Hodgkin's Lymphoma Pipeline

Hodgkin's Lymphoma Pipeline

Hodgkin's Lymphoma also known as Hodgkin's disease is a type of blood cancer that initiate in the lymphatic system (part of immune system that help to get rid of waste and fight against infections). This disease is the most common type of cancer of lymphatic system. Hodgkin disease originate in the WBCs and grow abnormally and spread beyond the lymphatic system. As the disease progress it invades into other organs and can damage their function. Hodgkin's lymphoma are more common in men than women and affect individuals between the age of 15-40 and above 55 years. The exact etiology of Hodgkin's Lymphoma is not clear however, DNA mutation, and infection of Epstein-Barr virus (EBV), which causes mononucleosis can be the reason behind the development of Hodgkin's lymphoma.

DelveInsight's, "Hodgkin's Lymphoma Pipeline Insight, 2023" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hodgkin's Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hodgkin's Lymphoma Key Players
• Affimed Therapeutics
• ACD Therapeutics
• Cstone Pharmaceuticals
• 4SC
• TG Therapeutics
• And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's Hodgkin's Lymphoma report covers around 10+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Some of Hodgkin's Lymphoma Therapies are:
• AFM 13
• Camidanlumab tesirine
• Sugemalimab
• Resminostat
• TGR-1202
• And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Current Hodgkin's Lymphoma Treatment Scenario and Hodgkin's Lymphoma Emerging Therapies:
• How many companies are developing Hodgkin's Lymphoma drugs?
• How many Hodgkin's Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hodgkin's Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hodgkin's Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hodgkin's Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Request for Free Sample Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents:
Introduction
Executive Summary
Hodgkin's Lymphoma: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Hodgkin's Lymphoma - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Hodgkin's Lymphoma companies' collaborations, Licensing, Acquisition -Deal Value Trends
Hodgkin's Lymphoma Collaboration Deals
Mid Stage Products (Phase II)
• Comparative Analysis
AFM 13:Affimed Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Camidanlumab tesirine: ACD Therapeutics
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Hodgkin's Lymphoma Key Companies
Hodgkin's Lymphoma Key Products
Hodgkin's Lymphoma- Unmet Needs
Hodgkin's Lymphoma- Market Drivers and Barriers
Hodgkin's Lymphoma- Future Perspectives and Conclusion
Hodgkin's Lymphoma Analyst Views
Hodgkin's Lymphoma Key Companies
Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/
Connect With Us at:
LinkedIn | Facebook | Twitter
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hodgkin's Lymphoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals and Many Others here

News-ID: 2940300 • Views:

More Releases from DelveInsight Business Research

Primary Biliary Cholangitis Market Expected to Experience Major Growth by 2034, According to DelveInsight
Primary Biliary Cholangitis Market Expected to Experience Major Growth by 2034, …
DelveInsight's "Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Primary Biliary Cholangitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Biliary Cholangitis
Advanced Renal Cell Carcinoma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight
Advanced Renal Cell Carcinoma Pipeline 2025: Therapies, MOA Insights, and Key Cl …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Advanced Renal Cell Carcinoma pipeline constitutes 50+ key companies continuously working towards developing 60+ Advanced Renal Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Advanced Renal Cell Carcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis b …
DelveInsight's "Alport Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology as well as the Alport Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Alport Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alport Syndrome Market Forecast https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Angioedema pipeline constitutes 20+ key companies continuously working towards developing 20+ Angioedema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Angioedema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed

All 5 Releases


More Releases for Hodgkin

Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%. Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/ Key Highlights Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025? The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The non hodgkin
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market. Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067 Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports. Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)